.
MergerLinks Header Logo

Announced

Completed

Aphria completed the merger with Tilray in a $3.9bn deal.

Financials

Edit Data
Transaction Value£2,915m
Consideration TypeOrdinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales5x
EV/EBITDA-
Share Price Premium23%
One Off Charge-

Tags

Edit

Majority

Farming Fishing Ranching and Plantations

cannabis cultivation

Canada

Domestic

Merger

Acquisition

Single Bidder

Friendly

Public

Reverse Takeover

Completed

Synopsis

Edit

Aphria, an international producer and distributor of medicinal and recreational cannabis, completed the merger with Tilray, a pharmaceutical company that develops cannabis based medicines, drugs, drops, and oil products, in a $3.9bn deal. "Tilray is poised to strike and transform the industry with our highly scalable operational footprint, a curated portfolio of diverse medical and adult-use cannabis brands and products, a multi-continent distribution network, and a robust capital structure to fund our global expansion strategy and deliver sustained profitability and long-term value for our stakeholders," Irwin Simon, Aphria CEO. On April 15, 2021, Aphria's shareholders approved the proposed merger With Tilray.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US